According to a recent report by Coherent Market Insights, the global pegfilgrastim biosimilars market is estimated to be valued at USD 1.84 Bn in 2025 and is expected to reach USD 3.39 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 9.1% from 2025 to 2032. The market is experiencing growth due to increasing demand from patients seeking more affordable alternatives to expensive reference biologic drugs. Biosimilars, which offer substantial cost savings, are becoming a preferred option. This trend is driving greater adoption of pegfilgrastim biosimilars by hospitals and cancer treatment centers.
Request for Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/7242
Global Medicine Pegfilgrastim Biosimilars Market Key Takeaways
• According to Coherent Market Insights (CMI), the global pegfilgrastim biosimilars market size is forecast to reach USD 1.84 Bn in 2025 to USD 3.39 Bn by 2032.
• Global demand for pegfilgrastim biosimilars is projected to increase at a robust CAGR of 9.1% throughout the assessment period.
• Based on product, pegfilgrastim biosimilars segment is set to dominate the industry, holding a revenue share of nearly 3/5 in 2025.
• By application, oncology segment is expected to account for more than half of the global pegfilgrastim biosimilars market share in 2025.
• Regarding route of administration, subcutaneous segment is anticipated to generate a revenue of about USD 1.29 Bn in 2025.
• North America leads the global pegfilgrastim biosimilars industry, holding a revenue share of over 2/5 in 2025. This is attributable to expanding application of pegfilgrastim biosimilars in oncology.
As per Coherent Market Insights’ latest pegfilgrastim biosimilars market analysis, Asia Pacific is expected to exhibit fastest growth during the assessment period. Rising cases of cancer and growing demand for cost-effective treatments will likely shape this growth.
Purchase Now Up to 25%% Discount on This Premium Research Report: https://www.coherentmarketinsights.com/insight/buy-now/7242
Rising Prevalence of Cancer Spurring Market Growth
Coherent Market Insights’ latest pegfilgrastim biosimilars market research report outlines prominent factors driving industry growth. Increasing incidence of cancer globally is one such growth driver.
According to the World Health Organization (WHO), global cancer cases are expected to increase by around 77% by 2050, reaching over 35 million new cases annually. This alarming increase in cancer burden is expected to drive demand for pegfilgrastim biosimilars.
Pegfilgrastim biosimilars are considered a prophylactic measure after chemotherapy to stimulate neutrophil production. They have the potential to effectively reduce the risk of febrile neutropenia in patients undergoing chemotherapy. Thus, higher the number of cancer cases, greater will be demand for supportive chemotherapy drugs like pegfilgrastim biosimilars.
Also Read: Biosimilar Contract Manufacturing Market Size, Share & Trends Analysis Report (2025-2032)
Regulatory Hurdles Restraining Pegfilgrastim Biosimilars Market Growth
The future pegfilgrastim biosimilars market outlook looks promising. However, regulatory challenges are expected to limit market growth to some extent during the assessment period.
Biosimilars like pegfilgrastim require rigorous regulatory approvals due to their complex biological nature. This poses a challenge for manufacturers of pegfilgrastim biosimilars. Similarly, lengthy clinical trials lead to high development costs as well as delayed market entry.
Growing Interest in Biosimilars Unlocking New Opportunities for Industry Players
Popularity of biosimilars, including pegfilgrastim biosimilars, is increasing rapidly. This is mainly due to their cost-effectiveness combined with comparable efficacy, purity, and safety to the original biologic drugs.
The cost advantage of biosimilars is expected to encourage more patients and healthcare providers to adopt these alternatives. This, in turn, will create significant growth opportunities for pegfilgrastim biosimilar manufacturers.
Regulatory bodies are also promoting development and adoption of biosimilars through initiatives like the FDA’s Biosimilar Action Plan. These initiatives are intended to increase treatment options and reduce healthcare costs. Rising number of such initiatives is expected to create a conducive environment for the growth of pegfilgrastim biosimilars market.
Impact of AI on the Pegfilgrastim Biosimilars Market
Artificial intelligence (AI) is becoming a key tool for manufacturers of pegfilgrastim biosimilars to enhance drug development, regulatory compliance, and market access strategies. AI-powered technologies accelerate biosimilar research by streamlining clinical trial design as well as predicting biologic behavior and ensuring high similarity with reference products.
AI also helps in pharmacovigilance by analyzing real-world data to monitor safety and efficacy after product launch. These innovations have the potential to reduce development costs and timelines as well as support personalized treatment approaches. They could foster greater adoption of pegfilgrastim biosimilars in oncology and hematology care.
Emerging Pegfilgrastim Biosimilars Market Trends
• Ongoing shift toward personalized medicine is anticipated to positively influence the pegfilgrastim biosimilars market value. As personalized oncology treatments become more prevalent, demand for supportive therapies like pegfilgrastim biosimilars is likely to rise, enabling industry players to align their offerings with evolving treatment paradigms.
• Development of long-acting biosimilars is emerging as a key growth-shaping trend in the pegfilgrastim biosimilars industry. Companies are focusing on developing longer-acting biosimilar formulations to improve patient convenience as well as adherence.
• Expansion of pegfilgrastim biosimilars in emerging markets will play a key role in boosting the industry. Nations like India and Russia are focusing on improving their healthcare capabilities as well as enhancing access to cost-effective medicines. This is expected to create lucrative growth opportunities for pegfilgrastim biosimilar companies.
• Pegfilgrastim biosimilars market price is also decreasing with new product launches. Industry players are constantly launching new biosimilars, leading to increased market competition and lower prices.
Also Read: Global Herceptin Biosimilar Market – Industry Trend and Forecast (2025-2032)
Analyst’s View
“The global pegfilgrastim biosimilars industry is set to exhibit robust growth, owing to rising prevalence of cancer, increasing demand for cost-effective medications, and favorable government support,” said senior analyst Ghanshyam Shrivastava.
Current Events and Their Impact on the Pegfilgrastin Biosimilars Market
|
Event |
Description and Impact |
|
Approval of Udenyca OnBody (pegfilgrastim-cbqv) from Coherus |
|
|
Increasing Oncology Drug Approvals by EMA and USFDA (2023–2024) |
|
|
Biosimilar Reimbursement Expansion in Asia-Pacific (2024) |
|
Competitor Insights
Key companies in pegfilgrastim biosimilars market report:
- Mylan N.V.
- Gedeon Richter
- Coherus BioSciences
- Intas Pharmaceuticals
- Biocon
- Apotex Inc.
- Dr. Reddy's Laboratories
- Cinfa Biotech
- Henlius Biotech
- Sandoz (a Novartis division)
- Biocad
- Pfizer Inc.
- Stada Arzneimittel AG
- Mundipharma
- Genor Biopharma
- Qilu Pharmaceutical
- Aurobindo Pharma
- Glenmark Pharmaceuticals
Key Developments
In January 2025, Shanghai Henlius Biotech, Inc. entered into a license and supply agreement with Abbott. This agreement grants Abbott exclusive or semi-exclusive rights to commercialize four biosimilars and one innovative biologic developed by Henlius across 69 emerging markets.
In February 2024, Coherus BioSciences launched Udenyca OnBody® (pegfilgrastim-cbqv) in the United States. This product is a biosimilar to Amgen’s Neulasta® and is administered post chemotherapy to reduce the incidence of infection, specifically febrile neutropenia.
Also Read: Cancer Biologics Market Size, Share, and Trends for 2025-2032
Our Trusted Partners:
Worldwide Market Reports, Coherent MI, Stratagem Market Insights
Get Recent News:
https://www.coherentmarketinsights.com/news
About Us:
Coherent Market Insights leads into data and analytics, audience
measurement, consumer behaviors, and market trend analysis. From shorter
dispatch to in-depth insights, CMI has exceled in offering research, analytics,
and consumer-focused shifts for nearly a decade. With cutting-edge syndicated
tools and custom-made research services, we empower businesses to move in the
direction of growth. We are multifunctional in our work scope and have 450+
seasoned consultants, analysts, and researchers across 26+ industries spread
out in 32+ countries.
Contact
Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: + 12524771362
UK: +442039578553
AUS: +61-2-4786-0457
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
For Latest Update Follow Us:
LinkedIn | Facebook | Twitter
